-
Conceptus Announces FDA Approval to Remove Nickel Contraindication From the Essure Procedure Instructions
Thursday, August 4, 2011 - 4:10pm | 54Conceptus, Inc. (Nasdaq: CPTS),developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that effective immediately, the U.S. Food and Drug Administration has approved the removal of the nickel hypersensitivity contraindication...
-
Rodman & Renshaw Maintains Abiomed Market Underperform, $10 PT
Thursday, August 4, 2011 - 3:53pm | 102Rodman & Renshaw maintained its Abiomed (NASDAQ: ABMD) Market Underperform rating and $10 price target in a research report published today. In the report, Rodman & Renshaw states, "Our due diligence checks with physicians suggest that the consensus view is “for the right patient the...
-
Pressure 08-04-2011
Thursday, August 4, 2011 - 3:38pm | 989Cusick's Corner Nowhere to hide -- except in Bonds and Gold. This is a large global distribution and I did not expect this kind of action, there is very little to get excited about today. The action has kicked longs out with stops and earnings and data at this stage is not going to move this train...
-
Wunderlich Securities Reiterates Abiomed Buy, $24 PT
Thursday, August 4, 2011 - 12:47pm | 72Wunderlich Securities reiterated its Abiomed (NASDAQ: ABMD) Buy rating and $24 price target in a research report published today. In the report, Wunderlich Securities states, "We expect several new catalysts for ABMD will emerge over the next few months, and we believe growth investors should...
-
Wunderlich Reiterates Buy Rating On Abiomed
Thursday, August 4, 2011 - 12:46pm | 47According to Wunderlich Securities, Abiomed (NASDAQ: ABMD) reported fiscal Q4 revenues this morning, essentially right in line with the estimates. Wunderlich said that revenues grew 25%, while Impella increased 33%. "We reiterate our Buy rating and $24 target." Abiomed closed yesterday at $15.24.
-
Options Brief: Mindray Medical International
Thursday, August 4, 2011 - 10:26am | 66Shares of Mindray Medical International (NYSE: MR) are lower on the session by 1.61%, trading at $25.73. Overall call volume is now running at 7.43x the daily average, with 40% of all calls traded being purchases on the offer. 1,003 contracts have traded on the session so far. Mindray Medical...
-
Rodman & Renshaw Maintains Market Outperform on Thoratec
Thursday, August 4, 2011 - 9:37am | 92Rodman & Renshaw is out with its report today on Thoratec (NASDAQ: THOR), maintaining Market Outperform. In its report, Rodman & Renshaw writes, "We are maintaining our OutPerform and our PT of $42 PT on THOR. Our PT represents approximately 6x our fiscal 2012 revenue estimate of $471...
-
Antares Pharma Announces Positive Study Results with VIBEX MTX in Rheumatoid Arthritis Patients
Thursday, August 4, 2011 - 9:02am | 100Antares Pharma, Inc. (NYSE: AIS) today announced the positive results of a clinical study evaluating VIBEX MTX, a proprietary auto injector product designed to give a rapid subcutaneous injection of methotrexate for the treatment of rheumatoid arthritis. The clinical pharmacokinetic study...
-
Morgan Stanley Reiterates Underweight and PT of $1.50 on Hansen Medical
Thursday, August 4, 2011 - 8:56am | 43Morgan Stanley reiterated its Underweight rating on Hansen Medical (NASDAQ: HNSN). At the same time, the rating agency left its price target on the company's stock unchanged at $1.50. On Wednesday, HNSN closed the day at $4.14.
-
Bank Of America Raises Price Target On Thoratec To $39
Thursday, August 4, 2011 - 8:54am | 118According to Bank of America, Thoratec (NASDAQ: THOR) reported a very strong Q2 last night with $111mm in revs (up 17% y/y) – nicely above the $104mm expected. Bank of America said that the most important indicator of future growth – unit sales of HM II – were up 21% in the US in Q2 and 20% OUS...
-
Wedbush Upgrades Thoratec To Neutral
Thursday, August 4, 2011 - 8:38am | 56According to Wedbush, Thoratec (NASDAQ: THOR) is upgraded to Neutral. Wedbush said that THOR reported Q2:2011 revenues of $111.2 million and EPS of $0.44, well above estimates of $103.7 million and $0.35, and consensus of $104.4 million and $0.35. “Raising fair value to $33 from $27 and upgrading...
-
Wedbush Upgrades Thoratec To Neutral, Raises PT To $33
Thursday, August 4, 2011 - 8:25am | 28Wedbush Securities has upgraded Thoratec Corporation (NASDAQ: THOR) from Underperform to Neutral and has raised the price target from $27 to $33.
-
Bank of America Raises PO on Thoratec To $39
Thursday, August 4, 2011 - 8:14am | 27Bank of America has raised the price objective on Thoratec (NASDAQ: THOR) from $33 to $39 and maintains its Buy rating.
-
UPDATE: Bank of America Lowers PT from $48 to $39 on Hill-Rom Holdings
Thursday, August 4, 2011 - 8:00am | 124Bank of America has published a report on Hill-Rom Holdings (NYSE: HRC) lowering the price target $9. In the report, Bank of America wrote, "HRC has fallen 24% since the Q3 miss last week versus a 5% decline in medtech and a 3% decline in the S&P. While HRC only lowered 2011 guidance by a...
-
Piper Jaffray Neutral On Thoratec
Thursday, August 4, 2011 - 7:49am | 99Piper Jaffray has a Neutral rating and a $27 price target on shares of Thoratec Corporation (NASDAQ: THOR) after it reported earnings. In a note to clients, Piper Jaffray writes, "Considering the significant beat in Q2 and the announced acquisition of Levitronix ($4M in acquired sales), we expect...